Gene editing, Life sciences, Oncology, T-Cell therapies, genome engineering, allogeneic, and off-the-shef CART therapies



Cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 18 years of expertise in gene editing � built on its flagship TALEN� technology and pioneering electroporation system PulseAgile � Cellectis uses the power of the immune system to target and eradicate cancer cells.
Using its life-science-focused, pioneering genome engineering technologies, Cellectis� goal is to create innovative products in multiple fields and with various target markets.